User:Dantalione/sandbox

Quinn Systems Incorporated (stylised as QuiSys, or QuiSys Inc.) is an American conglomerate, headquartered in Los Angeles. It has multiple subsidiaries, notably QuiSys Research, which is headquartered in Seattle, QuiSys Enforcement, which is headquartered in Dallas, and QuiSys International, which is headquartered in New York City.

QuiSys quickly rose in prominence after its’ formation in 2010, and is now considered one of the most influential companies in the United States. It predominantly provides support in the medical, military, scientific and infrastructure fields, and holds contracts with the federal government and multiple states. QuiSys performs research and development in modern pharmaceuticals, as well as operating multiple public hospital systems throughout the nation. Additionally, QuiSys has become the first company to fully privatise both the police force of many states and the federal peacekeeping taskforce.

QuiSys is publicly traded, and has a primary listing on the New York Stock Exchange and is a constituent of the FTSE 100 Index. It has secondary listings on the OMX exchange and the Dow Jones. The company has come under fire recently, for allegations that their privatisation of sectors which were formerly public has weakened the government and negatively impacted the people of the United States. The company denies all such allegations, and has stated on record that QuiSys simply wishes to provide “the best possible America, for all Americans.”

History
QuiSys was established in 2010, after its’ predecessors, Caixin Inc. and Roquel Pharmaceuticals merged and re-branded as a single entity. The CEO, Maria Quinn, and the board of directors stated at the time that QuiSys was “A company for the future of America.” It grew rapidly, after its’ development of a revolutionary new drug for treatment of melanoma. The drug, irethyl, set industry standards, and allowed QuiSys to gain influence amongst the scientific sector. Their acquisition of Bryris Co, AiRed Research, and LeoSenec solidified their position as one of the top organizations within the medical and scientific community.

QuiSys’ expansion into military and civil force was initially controversial , but its’ acquisition of Crane Defence Services in 2013 was declared to be simply a business decision, and was not intended to influence CDS’s normal operation. Ms. Quinn stated on record that "QuiSys’ investment [in CDS] will provide a stable financial support base, so that Crane Defence Services can continue to serve the American people in its’ highest capacity." The merger was nevertheless met with some forceful opposition.

See also: List of attempted sabotages to QuiSys properties

QuiSys continued to move into multiple industries, acquiring multiple contracts to operate hospitals across the nation.

Operations
QuiSys is split into twelve primary operating divisions: Primary Care, Specialty Care, Pharmaceuticals, Administration, Municipal Management, Research and Development, Crime Prevention, Special Weapons, Defense, Infrastructure, Emerging Markets  and Media Management.

QuiSys currently holds research and development labs in:
 * Stockton, California
 * Omaha, Nebraska
 * Juneau,  Alaska,
 * North Hempstead, New York
 * Fort Worth, Texas
 * Detroit, Michigan

Litigation
QuiSys is involved in a number of lawsuits regarding both their business mergers and purported ethical conflicts. As some of these cases are ongoing, this section will be updated frequently.

Damijani v. QuiSys Inc.
The first scandal that the company faced, this lawsuit was filed after one Rudolf Damijani was terminated from the company. Mr Damijani alleged that he was wrongfully fired for protesting against unethical business decisions, and attempted to prosecute. His suit was unsuccessful, and he was forced to pay compensation to QuiSys Inc.

GMO Virus
A scientist claimed she was infected by a genetically modified virus while working for QuiSys’ research laboratory in Stockton, California. In her federal lawsuit she stated that she had been intermittently paralyzed by the QuiSys-designed virus. "Ms. Dorine, of Lexington-Fayette, suspects she was inadvertently exposed, through work by a former QuiSys colleague in 2011 or 2012, to an engineered form of the lentivirus, which was being used at the time for classified infectious disease research.” The court found that Dorine failed to demonstrate that her illness was caused by exposure to the lentivirus, but ruled that QuiSys had violated on-site OH&S regulations. An audit was ordered, and the Stockton lab subsequently upgraded its’ on-site containment units.

Darcassan
QuiSys was recently fined for promoting Darcassan – approved at the time for major depressive disorder and also sold as an assistance for alcohol withdrawal, Philax – for weight loss and the treatment of attention deficit hyperactivity disorder, sexual dysfunction and substance addiction. Selective QuiSys executives  paid doctors in their hospitals to promote these off-label uses, and set up supposedly independent advisory boards. The company stated that these were isolated incidents, and that such promotion was  not part of QuiSys policy as a whole, but did not dispute the fine in court.

Doping in football
See also: The Martin Prue incident

On May 14, 2013, Martin Prue returned a positive doping test result for an unidentified drug-like substance in an out-of-competition control. Prue had been involved in recent QuiSys advertising campaigns, and immediately blamed the company for any substances that were present in his bloodstream. After multiple tests, independent laboratories were unable to verify exactly what chemical was utilised, and the case was dropped. Martine Prue vanished a week later, under suspicious circumstances. Some have claimed that QuiSys was involved, but no reports have ever been confirmed.

Galathel
In September 2016 QuiSys settled a lawsuit brought for $608 million to settle allegations that the company defrauded Medicare, Medicaid, and other government-funded health care programs in connection with its promotional practice and unethical pushing of Galathel, an antipsychotic with known detrimental side effects.

In June 2017, QuiSys settled a lawsuit in the United States totalling $15.7 million to be divided up to 12 states.

Allegations of Police Brutality
Since QuiSys has taken over the police departments of multiple states, allegations have arisen that officers trained under QuiSys are inclined to use more violent and aggressive tactics. Accusations of unnecessary force by QuiSys trained officers have become more common since 2017, following an incident where three policemen were convicted of using lethal force against an unarmed civilian. Leaked videos showed QuiSys-approved training materials included information that suggested that officers racially profile communities, ignore legal requirements regarding their service firearms, and conceal evidence of wrongdoing by co-workers.

The controversial videos prompted an outcry among marginalized communities, who accused QuiSys of worsening the racial and economic divides in American society. Multiple protests were staged around the trial of the officers, and despite their conviction, there continues to be vocal opposition to QuiSys' policing practices. Communities in which QuiSys controls the police force are frequently subject to attacks upon officers, sustained industrial and civil sabotage, and organized resistance. Some analysts have claimed that it is the fault of this opposition that QuiSys' tactics have become reliant upon lethal force in recent years. The development of QuiSys' specialised SWAT teams has also drawn criticism, with minority groups claiming that QuiSys SWAT forces are overly aggressive and commit unnecessary violence against innocents.